Autoimmune Diseases  >>  PF-5230895  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-5230895 / Emergent Biosolutions, Pfizer
NCT00641225: Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Completed
1
60
Canada, US
SBI-087
Pfizer, Emergent Product Development Seattle LLC
Rheumatoid Arthritis
03/11
03/11
NCT00815906: Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

Completed
1
20
Japan
SBI-087
Pfizer, Emergent Product Development Seattle LLC
Arthritis, Rheumatoid
04/12
05/12
NCT00714116: Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Checkmark Enrollment completion for P1 study for SLE
Jan 2012 - Jan 2012: Enrollment completion for P1 study for SLE
Completed
1
30
US
SBI-087
Pfizer, Emergent Product Development Seattle LLC
Lupus Erythematosus, Systemic
09/12
09/12

Download Options